+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

BNP and NTproBNP Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, 2020-2030

  • PDF Icon

    Report

  • 185 Pages
  • November 2025
  • Region: Global
  • TechSci Research
  • ID: 5941764
Free Webex Call
10% Free customization

Point Of Care Testing is the fastest growing segment, North America is the largest market globally

Free Webex Call

Speak directly to the analyst to clarify any post sales queries you may have.

10% Free customization

This report comes with 10% free customization, enabling you to add data that meets your specific business needs.

The Global BNP And NTproBNP Market, valued at USD 1.92 Billion in 2024, is projected to experience a CAGR of 7.15% to reach USD 2.91 Billion by 2030. Brain Natriuretic Peptide (BNP) and N-terminal pro-B-type Natriuretic Peptide (NT-proBNP) are cardiac biomarkers secreted by cardiomyocytes in response to ventricular stretch or pressure overload, serving as critical diagnostic indicators for heart failure and other cardiovascular conditions. The market for these diagnostic assays is substantially driven by the increasing global incidence of cardiovascular diseases and the expanding geriatric population, which is particularly susceptible to cardiac ailments.

Key Market Drivers

The growth of the Global BNP and NTproBNP Market is significantly influenced by the escalating prevalence of cardiovascular diseases and the expanding geriatric population increasingly susceptible to heart conditions. The rising incidence of cardiovascular diseases necessitates widespread diagnostic and prognostic tools like BNP and NTproBNP assays for early detection and disease management. According to the World Health Organization, in 2022, an estimated 19.8 million people died from cardiovascular diseases, highlighting the profound global health burden these conditions impose. Concurrently, the increasing longevity of populations worldwide contributes to a higher prevalence of age-related cardiac ailments. This demographic shift directly fuels demand for cardiac biomarkers.

Key Market Challenges

The inherent limited specificity of Brain Natriuretic Peptide and N-terminal pro-B-type Natriuretic Peptide tests significantly impedes market expansion. Elevated levels of these biomarkers can arise from various non-cardiac conditions, such as renal failure and pulmonary embolism, potentially leading to false-positive diagnoses and complicating clinical interpretation. This lack of singular diagnostic clarity diminishes confidence in the tests as standalone indicators for heart failure.

Key Market Trends

The expanding integration of point-of-care (PoC) testing represents a significant trend in the global BNP and NTproBNP market by decentralizing diagnostic capabilities and enabling rapid clinical decisions. PoC devices provide immediate results, crucial for managing acute cardiac events and enhancing patient throughput in emergency settings. This trend reflects a broader move towards more accessible and efficient diagnostic pathways. For instance, the American College of Cardiology in a journal scan from August 2024, highlighted a 2-hour strategy for point-of-care high-sensitivity cardiac troponin I testing in suspected acute myocardial infarction, underscoring the drive for expedited cardiac biomarker assessment.

Key Market Players Profiled:

  • Specim, Spectral Imaging Ltd
  • Gentian Diagnostics ASA
  • Siemens AG
  • PerkinElmer Inc
  • Biomerieux SA
  • Quidel Corporation
  • Bio-Rad Laboratories, Inc.
  • F. Hoffman-La Roche Ltd
  • BHR Pharmaceuticals Ltd.
  • Xiamen Biotime Biotechnology Co., Ltd.

Report Scope:

In this report, the Global BNP And NTproBNP Market has been segmented into the following categories:

By Type:

  • Brain Natriuretic Peptide
  • NT-proBNP (N-terminal Pro-B-Type Natriuretic Peptide)

By Location of Testing:

  • Point Of Care Testing
  • Laboratory Testing

By Application:

  • Myocardial Infarction
  • Congestive Heart Failure
  • Acute Coronary Syndrome (ACS)
  • Others

By Region:

  • North America
  • Europe
  • Asia Pacific
  • South America
  • Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global BNP And NTproBNP Market.

Available Customizations:

With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report:
  • Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.

Table of Contents

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global BNP And NTproBNP Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Type (Brain Natriuretic Peptide, NT-proBNP (N-terminal Pro-B-Type Natriuretic Peptide))
5.2.2. By Location of Testing (Point Of Care Testing, Laboratory Testing)
5.2.3. By Application (Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome (ACS), Others)
5.2.4. By Region
5.2.5. By Company (2024)
5.3. Market Map
6. North America BNP And NTproBNP Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Type
6.2.2. By Location of Testing
6.2.3. By Application
6.2.4. By Country
6.3. North America: Country Analysis
6.3.1. United States BNP And NTproBNP Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Type
6.3.1.2.2. By Location of Testing
6.3.1.2.3. By Application
6.3.2. Canada BNP And NTproBNP Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Type
6.3.2.2.2. By Location of Testing
6.3.2.2.3. By Application
6.3.3. Mexico BNP And NTproBNP Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Type
6.3.3.2.2. By Location of Testing
6.3.3.2.3. By Application
7. Europe BNP And NTproBNP Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Type
7.2.2. By Location of Testing
7.2.3. By Application
7.2.4. By Country
7.3. Europe: Country Analysis
7.3.1. Germany BNP And NTproBNP Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Type
7.3.1.2.2. By Location of Testing
7.3.1.2.3. By Application
7.3.2. France BNP And NTproBNP Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Type
7.3.2.2.2. By Location of Testing
7.3.2.2.3. By Application
7.3.3. United Kingdom BNP And NTproBNP Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Type
7.3.3.2.2. By Location of Testing
7.3.3.2.3. By Application
7.3.4. Italy BNP And NTproBNP Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Type
7.3.4.2.2. By Location of Testing
7.3.4.2.3. By Application
7.3.5. Spain BNP And NTproBNP Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Type
7.3.5.2.2. By Location of Testing
7.3.5.2.3. By Application
8. Asia Pacific BNP And NTproBNP Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Type
8.2.2. By Location of Testing
8.2.3. By Application
8.2.4. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China BNP And NTproBNP Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Type
8.3.1.2.2. By Location of Testing
8.3.1.2.3. By Application
8.3.2. India BNP And NTproBNP Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Type
8.3.2.2.2. By Location of Testing
8.3.2.2.3. By Application
8.3.3. Japan BNP And NTproBNP Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Type
8.3.3.2.2. By Location of Testing
8.3.3.2.3. By Application
8.3.4. South Korea BNP And NTproBNP Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Type
8.3.4.2.2. By Location of Testing
8.3.4.2.3. By Application
8.3.5. Australia BNP And NTproBNP Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Type
8.3.5.2.2. By Location of Testing
8.3.5.2.3. By Application
9. Middle East & Africa BNP And NTproBNP Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Type
9.2.2. By Location of Testing
9.2.3. By Application
9.2.4. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia BNP And NTproBNP Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Type
9.3.1.2.2. By Location of Testing
9.3.1.2.3. By Application
9.3.2. UAE BNP And NTproBNP Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Type
9.3.2.2.2. By Location of Testing
9.3.2.2.3. By Application
9.3.3. South Africa BNP And NTproBNP Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Type
9.3.3.2.2. By Location of Testing
9.3.3.2.3. By Application
10. South America BNP And NTproBNP Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Type
10.2.2. By Location of Testing
10.2.3. By Application
10.2.4. By Country
10.3. South America: Country Analysis
10.3.1. Brazil BNP And NTproBNP Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Type
10.3.1.2.2. By Location of Testing
10.3.1.2.3. By Application
10.3.2. Colombia BNP And NTproBNP Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Type
10.3.2.2.2. By Location of Testing
10.3.2.2.3. By Application
10.3.3. Argentina BNP And NTproBNP Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Type
10.3.3.2.2. By Location of Testing
10.3.3.2.3. By Application
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. Global BNP And NTproBNP Market: SWOT Analysis
14. Porter's Five Forces Analysis
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. Competitive Landscape
15.1. Specim, Spectral Imaging Ltd
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. Gentian Diagnostics ASA
15.3. Siemens AG
15.4. PerkinElmer Inc
15.5. Biomerieux SA
15.6. Quidel Corporation
15.7. Bio-Rad Laboratories, Inc.
15.8. F. Hoffman-La Roche Ltd
15.9. BHR Pharmaceuticals Ltd.
15.10. Xiamen Biotime Biotechnology Co., Ltd.
16. Strategic Recommendations17. About the Publisher & Disclaimer

Companies Mentioned

  • Specim, Spectral Imaging Ltd
  • Gentian Diagnostics ASA
  • Siemens AG
  • PerkinElmer Inc
  • Biomerieux SA
  • Quidel Corporation
  • Bio-Rad Laboratories, Inc.
  • F. Hoffman-La Roche Ltd
  • BHR Pharmaceuticals Ltd.
  • Xiamen Biotime Biotechnology Co., Ltd.

Table Information